IQV: Rounding Bottom detected on 17 Aug 2026

IQVIA, a leading global provider of clinical research services, is forming a rounding bottom pattern with the stock at $236.66, just 4.74 above resistance at $231.92. The pattern shows solid structure (14.0/15) and breakout quality (12.0/13), though volume is subdued at 0.61x average. With an overall score of 68 and 64.72% win probability, the setup indicates a transition from downtrend to accumulation. Current price sits 5.85% below the 52-week high and 53.18% above the 52-week low, positioning the stock in the upper half of its annual trading range. A secondary bullish pennant formed July 22 adds confluence.

IQVIA's stock has seen a 41.5% increase over the past three months, driven by strong R&D bookings and an optimistic revenue outlook for 2026. Q2 2026 results showed revenue of $4,368 million, up 8.7% year-over-year, with R&D Solutions net new bookings of $3.15 billion, up 19% year-over-year at a 1.22x book-to-bill ratio. The company raised its full-year 2026 guidance for revenue to between $17,275 million and $17,475 million. Mizuho Securities maintained a Buy rating on August 4, 2026, and RBC Capital raised its price target to $247 on July 29, while TD Cowen raised its target to $288. The pullback after this positive momentum creates the rounding bottom setup.

A successful rounding bottom breakout above $231.92 resistance would target the conservative measure of $246.91—representing just 4.4% upside from current levels. The pattern suggests the measured move correlates to the pattern amplitude, with invalidation occurring below key support at $154.50. Historical data for this pattern type shows 64.72% win probability according to the scoring model. Volume confirmation is critical; the current volume ratio of 0.61x needs to expand toward 1.2x+ on any breakout thrust to validate the reversal. RSI at 60.45 provides room to extend without overbought conditions developing immediately.

According to recent reports from August 4, 2026, top IQVIA insiders quietly cashed in on a major stock move, and on July 31, top insiders quietly unloaded millions in company stock. This insider selling contradicts the bullish narrative and warrants caution. The rounding bottom occurs after a 38.66% three-month rally, creating significant elevated valuation risk. Current volume of 905,610 shares trades at only 61% of the 20-day average, suggesting weak participation in this pattern formation—a red flag for conviction. With low beta at 0.63 and the stock trading near 52-week highs, downside protection is limited if sentiment shifts. The healthcare sector remains broadly bullish (regime score 0.95), but individual stock momentum can rapidly reverse when insiders are selling into strength.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.